Filana Therapeutics Reports Q3 Net Loss of $10.7 Million, $47 Million in Cash

Filana Therapeutics reported a Q3 2026 net loss of $10.7M, or $0.22 per share, with $47M in cash. The FDA lifted a clinical hold on simufilam for TSC-related epilepsy, and a Phase 2a study is expected to begin by Q1 2027. R&D expenses were $3.9M, down from $4M a year earlier. The company expects year-end cash to be $38M-$42M.

Original reporting
Published Nov 5, 2026, 1:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 1:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Filana Therapeutics Reports Q3 Net Loss of $10.7 Million, $47 Million in Cash — source image
Decision brief

The 30-second read

$FLNANeutralMed
01

Why it matters

The earnings release provides fresh financial metrics and a regulatory milestone that could influence valuation.

02

Market read

New earnings and FDA action create a short-term trading opportunity for FLNA.

03

What to watch

Cash runway of $47M and restricted $31.25M may sustain upcoming Phase 2a trial without dilution.

Relevance 6/10Novelty 7/10Timing: after-hours

Background

Filana Therapeutics (FLNA) is a clinical-stage biotech focused on treatments for TSC-related epilepsy.

Company-level read

Ticker impact

$FLNANeutralHigh confidence
Context

Filana Therapeutics disclosed Q3 2026 earnings, reporting a net loss of $10.7M and $47M cash, and announced FDA lifted clinical hold on simufilam.

Expected impact

potential modest upside as FDA lift reduces risk, but loss may limit gains

Evidence & confidence

New earnings data and FDA action are primary disclosures; investors will weigh loss against regulatory progress.

Market effects

Biotech sector may see slight uplift from FDA clearance signal.

US biotech investors could adjust positions; no broader regional effect.

Limited to investors tracking small-cap biotech pipelines.

Counterpoint

Loss magnitude may outweigh regulatory relief, prompting short pressure.

Key entities

  • Filana Therapeutics

    Biotech firm reporting Q3 results and FDA update.

  • FDA

    Lifted clinical hold on simufilam.

Related articles

$FLNAMed

Filana Therapeutics Reports Q3 2026 Financial Results and Provides Business Update

FILANA THERAPEUTICS, INC. (FLNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Filana Therapeutics Reports Q3 2026 Financial Results and Provides Business Update – Patient screening in Phase 2a study of simufilam in TSC-related epilepsy expected to begin by Q1 2027, following recent lift of FDA clinical hold – Recent publication in Cells 1 prov

$FLNAMedAI 8/10

Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy

FILANA THERAPEUTICS, INC. (FLNA) filed an SEC Form 8-K — Regulation FD Disclosure. EXHIBIT 99.1 Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy Patient screening for the Phase 2a study is expected to begin by the first quarter of 2027 Filana has engaged a leading clinical research organizatio

$FLNAMed

Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update

FILANA THERAPEUTICS, INC. (FLNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update AUSTIN, Texas, July 29, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing

$AZIOMedAI 8/10

Azio AI 3Q 2026: Revenue $1.87M, EPS ($0.34) — 10-Q Summary

Azio AI reported 3Q 2026 revenue of $1.87M, up 3.3% YoY, and a net loss of $0.34 per share, narrowed 9.7%. Sales were driven by medical supplies to a related party, while higher G&A costs, including a $860,428 stock-based compensation adjustment, offset gains from debt settlement. AI infrastructure segment generated no revenue.